[go: up one dir, main page]

PL2968269T3 - Sposób przygotowywania agonistów beta-3 i produktów pośrednich - Google Patents

Sposób przygotowywania agonistów beta-3 i produktów pośrednich

Info

Publication number
PL2968269T3
PL2968269T3 PL14768236T PL14768236T PL2968269T3 PL 2968269 T3 PL2968269 T3 PL 2968269T3 PL 14768236 T PL14768236 T PL 14768236T PL 14768236 T PL14768236 T PL 14768236T PL 2968269 T3 PL2968269 T3 PL 2968269T3
Authority
PL
Poland
Prior art keywords
agonists
intermediates
preparing beta
beta
preparing
Prior art date
Application number
PL14768236T
Other languages
English (en)
Inventor
Feng Xu
Zhuqing Liu
Richard Desmond
Jeonghan Park
Alexei Kalinin
Birgit Kosjek
Hallena Strotman
Hongmei Li
Johannah MONCECCHI
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51580798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2968269(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of PL2968269T3 publication Critical patent/PL2968269T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10Nitrogen as only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL14768236T 2013-03-15 2014-03-12 Sposób przygotowywania agonistów beta-3 i produktów pośrednich PL2968269T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791247P 2013-03-15 2013-03-15
PCT/US2014/023858 WO2014150639A1 (en) 2013-03-15 2014-03-12 Process for preparing beta 3 agonists and intermediates
EP14768236.3A EP2968269B1 (en) 2013-03-15 2014-03-12 Process for preparing beta 3 agonists and intermediates

Publications (1)

Publication Number Publication Date
PL2968269T3 true PL2968269T3 (pl) 2020-03-31

Family

ID=51580798

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14768236T PL2968269T3 (pl) 2013-03-15 2014-03-12 Sposób przygotowywania agonistów beta-3 i produktów pośrednich

Country Status (16)

Country Link
US (7) US10287289B2 (pl)
EP (2) EP3597737A1 (pl)
JP (1) JP6383403B2 (pl)
CY (1) CY1122690T1 (pl)
DK (1) DK2968269T3 (pl)
ES (1) ES2746801T3 (pl)
HR (1) HRP20191546T1 (pl)
HU (1) HUE045260T2 (pl)
LT (1) LT2968269T (pl)
ME (1) ME03506B (pl)
PL (1) PL2968269T3 (pl)
PT (1) PT2968269T (pl)
RS (1) RS59402B1 (pl)
SI (1) SI2968269T1 (pl)
SM (1) SMT201900508T1 (pl)
WO (1) WO2014150639A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013062878A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 angonists and intermediates
JP6063948B2 (ja) 2011-10-27 2017-01-18 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. ベータ3アゴニストおよび中間体を製造するプロセス
LT2968269T (lt) * 2013-03-15 2019-10-25 Merck Sharp & Dohme Beta 3 agonistų ir tarpinių junginių gamybos būdas
CN104496875B (zh) * 2014-12-12 2017-09-08 常州大学 2‑烯丙基‑2‑甲醛基‑n‑苯基吡咯碄的合成方法
KR20200012939A (ko) 2017-06-06 2020-02-05 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 투약
EP4410295A3 (en) 2017-06-06 2024-10-16 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CA3098536A1 (en) 2018-05-23 2019-11-28 Urovant Sciences Gmbh Use of vibegron to treat pain associated with irritable bowel syndrome
NZ774649A (en) 2018-12-05 2025-07-25 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
EP3941473A1 (en) 2019-03-18 2022-01-26 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
WO2022137178A1 (en) 2020-12-22 2022-06-30 Urovant Sciences Gmbh Methods of monitoring digoxin with concomitant use of vibegron to treat overactive bladder
TW202245781A (zh) 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍(vibegron)治療心臟衰竭之方法
CN113816917B (zh) * 2021-11-19 2022-02-18 奥锐特药业(天津)有限公司 一种维贝格龙中间体的制备方法
CN115850286B (zh) * 2022-12-05 2023-08-22 奥锐特药业(天津)有限公司 一种维贝格龙中间体及其制备方法
CN117467628B (zh) * 2023-09-18 2024-04-16 长兴制药股份有限公司 一种酮还原酶及其制备高光学纯度β-3肾上腺素能激动剂中间体的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
DOP2003000587A (es) 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
CN101855342B (zh) 2007-09-13 2013-07-10 科德克希思公司 用于还原苯乙酮的酮还原酶多肽
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2329014B1 (en) * 2008-08-29 2014-10-22 Codexis, Inc. Ketoreductase polypeptides for the stereoselective production of (4s)-3[(5s)-5(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
IN2012DN02782A (pl) 2009-10-07 2015-09-18 Merck Sharp & Dohme
US8748433B2 (en) * 2010-04-30 2014-06-10 Merck Sharp & Dohme Corp. β3 adrenergic receptor agonists
JP6063948B2 (ja) 2011-10-27 2017-01-18 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. ベータ3アゴニストおよび中間体を製造するプロセス
WO2013062878A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 angonists and intermediates
CN104053771B (zh) * 2011-11-18 2016-11-09 科德克希思公司 用于制备羟基取代的氨基甲酸酯的生物催化剂
LT2968269T (lt) 2013-03-15 2019-10-25 Merck Sharp & Dohme Beta 3 agonistų ir tarpinių junginių gamybos būdas

Also Published As

Publication number Publication date
US20200392141A1 (en) 2020-12-17
JP2016515117A (ja) 2016-05-26
HUE045260T2 (hu) 2019-12-30
SI2968269T1 (sl) 2019-12-31
US11091493B2 (en) 2021-08-17
PT2968269T (pt) 2019-10-08
US10287289B2 (en) 2019-05-14
SMT201900508T1 (it) 2019-11-13
WO2014150639A1 (en) 2014-09-25
EP3597737A1 (en) 2020-01-22
US11649243B2 (en) 2023-05-16
US20170145014A1 (en) 2017-05-25
ME03506B (me) 2020-04-20
US10696681B2 (en) 2020-06-30
US20250304588A1 (en) 2025-10-02
US20220073523A1 (en) 2022-03-10
EP2968269A1 (en) 2016-01-20
JP6383403B2 (ja) 2018-08-29
RS59402B1 (sr) 2019-11-29
CY1122690T1 (el) 2021-03-12
EP2968269A4 (en) 2016-12-28
DK2968269T3 (da) 2019-10-07
EP2968269B1 (en) 2019-07-10
US20240300955A1 (en) 2024-09-12
ES2746801T3 (es) 2020-03-06
US12180219B2 (en) 2024-12-31
LT2968269T (lt) 2019-10-25
US20190194211A1 (en) 2019-06-27
US20240300960A1 (en) 2024-09-12
HRP20191546T1 (hr) 2019-11-29

Similar Documents

Publication Publication Date Title
PL2968269T3 (pl) Sposób przygotowywania agonistów beta-3 i produktów pośrednich
IL269227B (en) Solid forms of treprostinil
HRP20190233T1 (hr) Postupci i intermedijeri za dobivanje inhibitora jak
IL246002A0 (en) Novel methods
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
LT3290407T (lt) Bromodomeno inhibitoriai
DK3015467T3 (da) Morpholino-oligonukleotidfremstillingsfremgangsmåde
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
PL2941442T3 (pl) Sposób wytwarzania mikrofibrylarnej celulozy
HUE036383T2 (hu) Bevonási eljárás
DK3010352T3 (da) Fremgangsmåde til fremstilling af fodertilsætning
PT2953948T (pt) Antagonistas de integrina fluorada
LT3038654T (lt) Naujas panaudojimas
LT3007726T (lt) Tautopatijos gydymo būdai
DK2970235T3 (da) Nye inhibitorer
DK2943561T3 (da) Fotobioreaktor
LT3369724T (lt) Iopamidolio gamybos būdas
BR112015021083A2 (pt) método
EP2945942A4 (en) Voriconazole IMMUNOASSAY
FR3001759B1 (fr) Rouge aubagee de turbomachine
BR112015029076A2 (pt) método
FI20135341L (fi) Menetelmä biopolttoaineen valmistamiseksi ja biopolttoaineen käyttö
IL239971A0 (en) Isometheptene isomer
DK3047028T3 (da) Fermenteringsfremgangsmåde